Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1964 2
1967 2
1968 1
1969 1
1970 2
1971 3
1972 1
1973 2
1975 2
1976 1
1977 2
1978 1
1981 6
1982 2
1983 1
1984 3
1985 4
1986 2
1987 1
1988 2
1989 4
1990 10
1991 3
1992 2
1993 2
1995 4
1996 7
1997 5
1998 6
1999 6
2000 7
2001 8
2002 4
2003 6
2004 8
2005 9
2006 9
2007 10
2008 8
2009 4
2010 17
2011 10
2012 14
2013 12
2014 16
2015 10
2016 17
2017 18
2018 8
2019 9
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

274 results
Results by year
Filters applied: . Clear all
Page 1
Neonatal characteristics and perinatal complications in neonates with Down syndrome.
Ergaz-Shaltiel Z, Engel O, Erlichman I, Naveh Y, Schimmel MS, Tenenbaum A. Ergaz-Shaltiel Z, et al. Am J Med Genet A. 2017 May;173(5):1279-1286. doi: 10.1002/ajmg.a.38165. Epub 2017 Apr 6. Am J Med Genet A. 2017. PMID: 28386951
Mortality during the primary hospitalization was 3.7%. The most common anomalies were cardiac (79%) with either congenital defects or functional abnormalities, neither influenced the length of hospitalization. ...
Mortality during the primary hospitalization was 3.7%. The most common anomalies were cardiac (79%) with either congenital defects or
Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial.
Uffmann M, Rasche M, Zimmermann M, von Neuhoff C, Creutzig U, Dworzak M, Scheffers L, Hasle H, Zwaan CM, Reinhardt D, Klusmann JH. Uffmann M, et al. Blood. 2017 Jun 22;129(25):3314-3321. doi: 10.1182/blood-2017-01-765057. Epub 2017 Apr 11. Blood. 2017. PMID: 28400376 Clinical Trial.
Still, 5-year overall survival (89% ± 3% vs 90% ± 4%; P(log-rank) = .64), event-free survival (EFS; 87% ± 3% vs 89% ± 4%; P(log-rank) = .71), and cumulative incidence of relapse/nonresponse (CIR/NR; 6% ± 3% vs 6% ± 2%; P(Gray) = .03) did not significantly differ bet …
Still, 5-year overall survival (89% ± 3% vs 90% ± 4%; P(log-rank) = .64), event-free survival (EFS; 87% ± 3% vs 89% ± 4%; P(lo …
Surgical Treatment for Congenital Heart Defects in Down Syndrome Patients.
Santos FCGB, Croti UA, Marchi CH, Murakami AN, Brachine JDP, Borim BC, Finoti RG, Godoy MF. Santos FCGB, et al. Braz J Cardiovasc Surg. 2019 Jan-Feb;34(1):1-7. doi: 10.21470/1678-9741-2018-0358. Braz J Cardiovasc Surg. 2019. PMID: 30810666 Free PMC article. Clinical Trial.
The data included gender, age, prematurity, weight, preoperative procedures, diagnosis, associated cardiac and non-cardiac anomalies, Risk Adjustment for Congenital Heart Surgery (RACHS-1), type of surgery, cardiopulmonary bypass (CPB), perfusion time, aortic clamping time and CP …
The data included gender, age, prematurity, weight, preoperative procedures, diagnosis, associated cardiac and non-cardiac anomalies, Risk A …
Down Syndrome and the Risk of Severe RSV Infection: A Meta-analysis.
Beckhaus AA, Castro-Rodriguez JA. Beckhaus AA, et al. Pediatrics. 2018 Sep;142(3):e20180225. doi: 10.1542/peds.2018-0225. Epub 2018 Aug 9. Pediatrics. 2018. PMID: 30093540 Free article.
STUDY SELECTION: All cohorts or case-control studies of DS with an assessment of RSV infection and the associated morbidity or mortality were included without language restriction. ...The primary outcomes were hospital admission and mortality. Secondary outcomes inc …
STUDY SELECTION: All cohorts or case-control studies of DS with an assessment of RSV infection and the associated morbidity or mortality
Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study.
Flasinski M, Scheibke K, Zimmermann M, Creutzig U, Reinhardt K, Verwer F, de Haas V, van der Velden VHJ, von Neuhoff C, Zwaan CM, Reinhardt D, Klusmann JH. Flasinski M, et al. Blood Adv. 2018 Jul 10;2(13):1532-1540. doi: 10.1182/bloodadvances.2018018945. Blood Adv. 2018. PMID: 29959152 Free PMC article. Clinical Trial.
The 5-year probability of event-free and overall survival of 102 enrolled TMD patients was 72 ± 5% and 91 ± 3%, respectively. ...Thus, low-dose cytarabine treatment helped to reduce TMD-related mortality when compared with the historical control but was insufficient …
The 5-year probability of event-free and overall survival of 102 enrolled TMD patients was 72 ± 5% and 91 ± 3%, respectively. ...Thus …
Characteristics and outcomes of children with acute myeloid leukemia and Down syndrome who are ineligible for clinical trials due to severe comorbidities.
Nakashima K, Hasegawa D, Tomizawa D, Miyamura T, Hama A, Iwamoto S, Terui K, Adachi S, Taga T. Nakashima K, et al. Pediatr Blood Cancer. 2019 Nov;66(11):e27942. doi: 10.1002/pbc.27942. Epub 2019 Aug 18. Pediatr Blood Cancer. 2019. PMID: 31423753
BACKGROUND: High survival rates of 80-90% have been reported in recent clinical trials of reduced-intensity chemotherapies for children with acute myeloid leukemia and Down syndrome (AML-DS). ...The 5-year overall survival rate was 51%. CONCLUSIONS: The prognosis of …
BACKGROUND: High survival rates of 80-90% have been reported in recent clinical trials of reduced-intensity chemotherapies for childr …
Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R, Lee DW, Pepper OB, Azorsa DO, Arceci RJ, Aleem E. Bista R, et al. J Exp Clin Cancer Res. 2017 Feb 1;36(1):22. doi: 10.1186/s13046-017-0493-5. J Exp Clin Cancer Res. 2017. PMID: 28143565 Free PMC article.
BTZ-resistance conferred increased resistance to Ara-C due to G1 arrest in the CMY-BR cells, which protected the cells from S-phase damage by Ara-C. ...
BTZ-resistance conferred increased resistance to Ara-C due to G1 arrest in the CMY-BR cells, which protected the cells from S-phase d …
Acute lymphoblastic leukemia in children with Down syndrome: Comparative analysis versus patients without Down syndrome.
Pennella CL, Rossi JG, Baialardo EM, Alonso CN, Guitter MR, Sánchez La Rosa CG, Millán NC, Alfaro EM, Zubizarreta PA, Felice MS. Pennella CL, et al. Arch Argent Pediatr. 2018 Aug 1;116(4):e500-e507. doi: 10.5546/aap.2018.eng.e500. Arch Argent Pediatr. 2018. PMID: 30016023 Free article. English, Spanish.

They showed a better response rate to prednisone (p= 0.09) and a higher mortality in induction and complete remission (p < 0.0001). ...CONCLUSIONS: A lower survival was observed among children aged 6-9 years with DS-ALL. Although these children showed a better ea

They showed a better response rate to prednisone (p= 0.09) and a higher mortality in induction and complete remission (p < 0.0001)

Characteristics and survival of children with acute leukemia with Down syndrome or other birth defects in New York State.
Qiao B, Austin AA, Schymura MJ, Browne ML. Qiao B, et al. Cancer Epidemiol. 2018 Dec;57:68-73. doi: 10.1016/j.canep.2018.10.004. Epub 2018 Oct 13. Cancer Epidemiol. 2018. PMID: 30326394
Survivals were similar among three groups. Among 563 AML children, 11.0% had DS, 6.0% had other birth defects, and 83.0% had no birth defects. ...Comparable survival was observed for ALL children. However, AML children with DS demonstrated superior survival c
Survivals were similar among three groups. Among 563 AML children, 11.0% had DS, 6.0% had other birth defects, and 83.0% had no birth
274 results
Jump to page
Feedback